Liver pressure drug trial halted early – what we know
NCT ID NCT05282121
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 25 times
Summary
This study tested a new medicine called Avenciguat (BI 685509) to lower high blood pressure in the liver's main vein, a condition called portal hypertension, in people with compensated cirrhosis. About 90 adults with cirrhosis from hepatitis B, C, or NASH took the drug alone or with empagliflozin for 8 weeks. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH - Medical University of Vienna
Vienna, 1090, Austria
-
American Research Corporation
San Antonio, Texas, 78215, United States
-
Amsterdam UMC, location VUMC
Amsterdam, 1105 AZ, Netherlands
-
Azienda Ospedaliera Policlinico di Modena
Modena, 41124, Italy
-
Beijing Friendship Hospital
Beijing, 100050, China
-
California Liver Research Institute
Pasadena, California, 91105, United States
-
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
-
Edegem - UNIV UZ Antwerpen
Edegem, 2650, Belgium
-
Floridian Clinical Research-Miami Lakes-68368
Miami Lakes, Florida, 33016, United States
-
HOP Beaujon
Clichy, 92118, France
-
HOP Rangueil
Toulouse, 31059, France
-
Hospital Britanico de Buenos Aires
CABA, 1280AEB, Argentina
-
Hospital Italiano de Buenos Aires
CABA, C1199ABB, Argentina
-
Hospital Ramón y Cajal
Madrid, 28034, Spain
-
Hospital Vall d'Hebron
Barcelona, 08035, Spain
-
Hvidovre Hospital
Hvidovre, 2650, Denmark
-
Inland Empire Clinical Trials, LLC
Rialto, California, 92377, United States
-
Medizinische Hochschule Hannover
Hanover, 30625, Germany
-
NanFang Hosptial
Guangzhou, 510515, China
-
National Hospital Organization Yokohama Medical Center
Kanagawa, Yokohama, 245-8575, Japan
-
Osaka Metropolitan University Hospital
Osaka, Osaka, 545-8586, Japan
-
Ospedale Civile di Baggiovara
Baggiovara (MO), 41126, Italy
-
Policlinico "Paolo Giaccone"
Palermo, 90127, Italy
-
Rambam Medical Center
Haifa, 31096, Israel
-
Regional Institute of Gastroenterology Hepatology "Prof. Dr. O. Fodor"
Cluj-Napoca, 400000, Romania
-
Singapore General Hospital
Singapore, 169608, Singapore
-
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, 310015, China
-
Universitätsklinikum Münster
Münster, 48149, Germany
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, 55131, Germany
-
Western Galilee Hospital
Nahariya, 2210001, Israel
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.